Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

NEXT STORY
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
PREV STORY
Intuitive Announces Third Quarter Earnings
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy

author_avatar
NASDAQ Market News

Global Infusion Pumps Industry

author_avatar
NASDAQ Market News

iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

author_avatar
NASDAQ Market News